{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:39:17Z","timestamp":1792719557340,"version":"4.5.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.aohep.2026.102470","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:24:41Z","timestamp":1792718681000},"page":"102470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium-glucose cotransporter-2 inhibitors and mortality and liver-related outcomes in patients with alcoholic cirrhosis, type 2 diabetes, and obesity"],"prefix":"10.1016","author":[{"given":"Mohamad Mahdi","family":"Osman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar T","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian J","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.aohep.2026.102470_bib0001","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1161\/CIR.0000000000000766","article-title":"Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association","volume":"141","author":"Arnold","year":"2020","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.aohep.2026.102470_bib0002","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMcp2000280","article-title":"Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes","volume":"384","author":"Kalyani","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.aohep.2026.102470_bib0003","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jacc.2019.11.036","article-title":"Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.aohep.2026.102470_bib0004","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.aohep.2026.102470_bib0005","doi-asserted-by":"crossref","first-page":"106","DOI":"10.14309\/ajg.0000000000000833","article-title":"Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers","volume":"116","author":"Whitfield","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.aohep.2026.102470_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.18470","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and Serious Liver Events in Patients With Cirrhosis","volume":"8","author":"Abu-Hammour","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.aohep.2026.102470_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.60429","article-title":"SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis","volume":"9","author":"Chung","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.aohep.2026.102470_bib0008","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12916-026-04629-x","article-title":"SGLT-2 Inhibitor use and liver-related and mortality outcomes in patients with type 2 diabetes and compensated cirrhosis","volume":"24","author":"Chou","year":"2026","journal-title":"BMC Med"},{"key":"10.1016\/j.aohep.2026.102470_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.aohep.2026.102470_bib0010","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.3390\/jcm12062253","article-title":"The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review","volume":"12","author":"Miyamoto","year":"2023","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.aohep.2026.102470_bib0011","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.aohep.2026.102470_bib0012","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/liv.15851","article-title":"Sodium-glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use","volume":"44","author":"Siafarikas","year":"2024","journal-title":"Liver Int"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126002905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126002905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:24:42Z","timestamp":1792718682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268126002905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":12,"alternative-id":["S1665268126002905"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102470","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-glucose cotransporter-2 inhibitors and mortality and liver-related outcomes in patients with alcoholic cirrhosis, type 2 diabetes, and obesity","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102470"}}